| 1478 |
National Cancer Institute |
Html |
en |
Skin Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of skin cancer. |
| treatment | 0.409923 |
| metastatic basal cell | 0.400394 |
| subsequent basal cell | 0.391984 |
| Skin Cancer Prevention | 0.365074 |
| Arch Dermatol | 0.471327 |
| photodynamic therapy | 0.399886 |
| sun-exposed skin | 0.375699 |
| skin cancers | 0.433811 |
| primary skin cancers | 0.370681 |
| uncomplicated basal cell | 0.398522 |
| basal-cell carcinoma | 0.373761 |
| PUBMED Abstract | 0.376972 |
| Mohs micrographic surgery | 0.406259 |
| Invest Dermatol | 0.363857 |
| prior skin cancer | 0.363746 |
| multiple basal cell | 0.397256 |
| nonmelanoma skin cancers | 0.400983 |
| recurrence rates | 0.396208 |
| Dermatol Surg Oncol | 0.421496 |
| periocular basal cell | 0.39808 |
| BCC | 0.370104 |
| Abstract | 0.389392 |
| main skin cancer | 0.382703 |
| basal cell nevus | 0.404293 |
|
| squamous cell carcinomas | 0.385705 |
| eyelid addresses carcinomas | 0.365517 |
| non-eyelid skin cancers | 0.367643 |
| surgical excision | 0.369879 |
| Br J Dermatol | 0.407426 |
| cosmetic results | 0.379562 |
| superficial basal cell | 0.487048 |
| skin cancer awareness | 0.383438 |
| basal cell carcinomas | 0.527823 |
| nodular skin BCCs | 0.369486 |
| nodular basal cell | 0.432753 |
| nonmelanoma skin cancers. | 0.373768 |
| nevoid Basal cell | 0.396437 |
| primary superficial basal | 0.391239 |
| radiation therapy | 0.475907 |
| nonmelanoma skin cancer | 0.483068 |
| basal cell carcinoma | 0.980145 |
| regional lymph nodes | 0.369237 |
| radiation therapy treatment | 0.376744 |
| longstanding skin ulcers | 0.361677 |
| et al. | 0.442813 |
| Acad Dermatol | 0.422124 |
| squamous cell carcinoma | 0.41423 |
|
CLICK HERE |
| 1490 |
National Cancer Institute |
Html |
en |
Hypopharyngeal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of hypopharyngeal cancer. |
| statistically significant survival | 0.552817 |
| pharynx cancer incidence | 0.54678 |
| hypopharyngeal SCCs | 0.568302 |
| United States | 0.594562 |
| Multiple primary tumors | 0.590618 |
| hypopharyngeal wall tumors | 0.623965 |
| neck squamous cell | 0.598149 |
| PUBMED Abstract | 0.631322 |
| pharyngeal cancer | 0.54424 |
| 5-year disease-free survival | 0.561931 |
| Otolaryngol Head Neck | 0.607335 |
| squamous cell | 0.712263 |
| hypopharyngeal carcinomas | 0.629276 |
| neck cancer patients | 0.603767 |
| Cancer Res | 0.688393 |
| squamous cell cancer | 0.573486 |
| hypopharyngeal tumor | 0.566864 |
| Abstract | 0.707746 |
| pyriform sinus | 0.633965 |
| functional larynx | 0.541602 |
| patients | 0.659221 |
| Hypopharyngeal carcinoma | 0.566532 |
| induction chemotherapy arm | 0.707576 |
| hypopharyngeal squamous cell | 0.623336 |
|
| squamous cell carcinomas | 0.681165 |
| hypopharyngeal SCC | 0.56973 |
| upper alimentary tract | 0.554127 |
| Natl Cancer Inst | 0.619483 |
| pyriform sinus cancer | 0.551602 |
| immediate surgery arm | 0.623979 |
| neoadjuvant chemotherapy | 0.990124 |
| field cancerization | 0.600816 |
| hypopharyngeal cancer. | 0.653244 |
| significant survival advantage | 0.54752 |
| neck cancer | 0.685166 |
| Clin Cancer Res | 0.614389 |
| radiation therapy | 0.868288 |
| Head Neck Surg | 0.701435 |
| hypopharyngeal cancers | 0.604268 |
| squamous carcinoma | 0.542607 |
| induction chemotherapy | 0.745083 |
| posterior pharyngeal wall | 0.598262 |
| hypopharyngeal cancer | 0.866148 |
| prospective randomized trial | 0.63031 |
| retrospective study | 0.58561 |
| squamous cell carcinoma | 0.669554 |
| standard adjuvant therapy | 0.638264 |
|
CLICK HERE |
| 1670 |
National Cancer Institute |
Html |
en |
Oral Cavity and Oropharyngeal Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for oral cancer. |
| cancer treatment | 0.462069 |
| cancer screening methods | 0.510918 |
| ongoing clinical trials | 0.459171 |
| following PDQ summaries | 0.498704 |
| PDQ cancer information | 0.601619 |
| squamous cells | 0.461192 |
| Oropharyngeal cancer forms | 0.542461 |
| clinical trials | 0.552349 |
| test result | 0.478895 |
| cancer information summary | 0.545028 |
| clinical trial | 0.464502 |
| breast cancer prevention | 0.475292 |
| fluorescent mouth rinse | 0.459409 |
| PDQ Oral Cavity | 0.538179 |
| cancer patients | 0.455495 |
| latest published information | 0.461223 |
| Oropharyngeal Cancer Prevention | 0.539186 |
| NCI’s PDQ | 0.469112 |
| cancer symptoms | 0.470328 |
| NCI PDQ cancer | 0.519444 |
| tests | 0.472016 |
| certain types | 0.45905 |
| Oral cavity cancer | 0.562303 |
| PDQ Screening | 0.487794 |
|
| treatment | 0.479473 |
| abnormal tissue | 0.496498 |
| screening tests | 0.460194 |
| oropharyngeal cancers | 0.542436 |
| Cancer Information Service | 0.4864 |
| Prevention Editorial Board | 0.494212 |
| treatment clinical trials | 0.460544 |
| National Cancer Institute | 0.552754 |
| PDQ documents | 0.4638 |
| new treatment | 0.461424 |
| Cancer screening trials | 0.51442 |
| oropharyngeal cancer screening | 0.581362 |
| Cancer Care page | 0.477739 |
| PDQ database | 0.466412 |
| PDQ summary | 0.507494 |
| cells | 0.483262 |
| abnormal red patch | 0.460863 |
| abnormal white patch | 0.460254 |
| cancer information summaries | 0.491365 |
| oral cavity | 0.970425 |
| comprehensive cancer information | 0.49122 |
| cancer | 0.792804 |
| oropharyngeal cancer | 0.758721 |
| early stage | 0.462272 |
|
CLICK HERE |
| 1688 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cancer treatment | 0.54874 |
| PDQ Cannabis | 0.53541 |
| PDQ cancer information | 0.561631 |
| Cancer Complementary | 0.483651 |
| cancer therapy | 0.493942 |
| clinical trials | 0.738523 |
| cannabinoid receptors | 0.573547 |
| advanced cancer patients | 0.489779 |
| U.S. Food | 0.49892 |
| cancer information summary | 0.529639 |
| National Institutes | 0.485607 |
| alternative cancer therapies | 0.482187 |
| clinical trial | 0.556349 |
| cancer therapies | 0.496308 |
| patients | 0.580973 |
| cancer patients | 0.559766 |
| Cannabis users | 0.54158 |
| Investigational New Drug | 0.490753 |
| NCI PDQ cancer | 0.493719 |
| cancer information database | 0.48226 |
| effects | 0.498728 |
| cannabinoids | 0.769857 |
| main active cannabinoid | 0.509915 |
| treatment | 0.563891 |
|
| breast cancer cells | 0.497802 |
| Cannabis plant extract | 0.540785 |
| United States | 0.581783 |
| Cannabis plant | 0.559258 |
| Complementary Therapies Editorial | 0.487662 |
| Drug Administration | 0.596753 |
| Cancer Information Specialist | 0.479354 |
| cancer cells | 0.516435 |
| Cancer Information Service | 0.529301 |
| Cannabis extract | 0.551963 |
| National Cancer Institute | 0.60295 |
| studies | 0.507275 |
| alternative medicine | 0.50524 |
| pain relief | 0.516491 |
| advanced cancer | 0.497262 |
| approved research settings | 0.478938 |
| cannabis | 0.903862 |
| chemotherapy-related nausea | 0.514076 |
| cancer cell death | 0.500487 |
| medicinal Cannabis | 0.540165 |
| cancer clinical trials | 0.488981 |
| alternative therapies | 0.483937 |
| cancer information summaries | 0.482387 |
| cancer | 0.807964 |
|
CLICK HERE |
| 1798 |
National Cancer Institute |
Html |
es |
Aflicción, duelo y manejo de la pérdida (PDQ®)–Versión para pacientes |
Informe revisado por expertos acerca de la aflicción, el duelo y los sentimientos de pérdida de los sobrevivientes de alguien que murió de cáncer. Se trata también la aflicción en los niños. |
| cope with grief | 0.320516 |
| Helping Children | 0.322023 |
| Dialogue Between Parent | 0.307208 |
| Wolfelt A | 0.31079 |
| Hemisphere Publishing Corporation | 0.30651 |
| siguientes preguntas | 0.304497 |
| Corr CA | 0.321186 |
| aflicción anticipatoria | 0.975865 |
| Do We Tell | 0.306573 |
| baja autoestima | 0.304526 |
| Aflicción normalLa | 0.370032 |
| Aflicción crónica | 0.366865 |
| Instituto Nacional | 0.309451 |
| cansancio extremo | 0.305043 |
| GP Putnam Sons | 0.306438 |
| Mourning Children | 0.305247 |
| familiar cercano | 0.304362 |
| When Someone Dies | 0.30744 |
| siguientes libros | 0.304582 |
| Tiffault BW | 0.304106 |
| años todavÃa | 0.304515 |
| Help Children Participate | 0.307506 |
| TCC ayuda | 0.305556 |
| religión ayuda | 0.304338 |
| muerte ayuda | 0.319844 |
|
| desarrollo edad comprensión | 0.306829 |
| Remember Someone You | 0.30677 |
| muerte expresiones | 0.319738 |
| PDQ Aflicción | 0.353557 |
| conversación).El tratamiento | 0.305805 |
| aflicción anticipatoria ayuda | 0.436499 |
| Publishing Company | 0.310219 |
| National Cancer Institute | 0.305834 |
| anticipatoriaLa aflicción anticipatoria | 0.37147 |
| siguientes riesgos | 0.304531 |
| New York | 0.346791 |
| Children Mourning | 0.305247 |
| siguientes factores | 0.316168 |
| Physician Data Query | 0.319434 |
| MÃnima reacción | 0.30471 |
| Mountain Rainbow Publications | 0.306521 |
| Talking About Death | 0.30672 |
| Springer Publishing Company | 0.306508 |
| Children Cope with | 0.321223 |
| Parent Dies | 0.311854 |
| Tenth Good Thing | 0.306668 |
| Helping Children Cope | 0.321422 |
| Helping Children Understand | 0.308268 |
| Accelerated Development | 0.311496 |
|
CLICK HERE |
| 1894 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas. |
| radiocirugÃa estereotáctica | 0.521736 |
| cuáles ganglios | 0.544229 |
| estadio iv | 0.535294 |
| pequeño corte | 0.516426 |
| sustancia llamada fcev | 0.511226 |
| faja ajustadora | 0.518847 |
| pequeña cantidad | 0.570347 |
| Silbido respiratorio | 0.522024 |
| cáncer.ampliar broncoscopia | 0.521373 |
| gen alk | 0.51503 |
| cáncer.ampliar mediastinoscopÃa | 0.517089 |
| células normales.ampliar exploración | 0.600106 |
| cuerpo.ampliar radiografÃa | 0.522592 |
| estadios ia | 0.514018 |
| rayos x | 0.552576 |
| estadio ib | 0.557189 |
| estadio ia | 0.556394 |
| enlace drugs approved | 0.531609 |
| ondas sonoras | 0.51647 |
| Non-Small Cell Lung | 0.531866 |
| células t | 0.528626 |
| vÃas respiratorias | 0.808836 |
|
| carcinoma epidermoide | 0.525518 |
| numerosos ensayos | 0.516625 |
| pecho.ampliar biopsia | 0.526618 |
| estadios iia | 0.515213 |
| estadio iiia | 0.625519 |
| determinadas células | 0.530359 |
| antecedentes familiares | 0.518918 |
| alta potencia | 0.516655 |
| estadio iia | 0.557019 |
| tirosina cinasa | 0.692486 |
| Cell Lung Cancer | 0.531364 |
| siguientes sitios | 0.51534 |
| siguientes situaciones | 0.666362 |
| ecografÃa ayuda | 0.515534 |
| principal factor | 0.576142 |
| áreas.ampliar biopsia | 0.52208 |
| siguientes formas | 0.529859 |
| bronquiolos.ampliar anatomÃa | 0.52368 |
| siguientes sumarios | 0.532291 |
| siguientes pruebas | 0.527678 |
| vasos sanguÃneos | 0.979174 |
|
CLICK HERE |
| 1951 |
National Cancer Institute |
Html |
es |
Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos. |
| siguientes procedimientos | 0.408317 |
| displasia multilinaje | 0.404818 |
| células madre | 0.698581 |
| leucemia aguda | 0.40611 |
| sÃndromes mielodisplásicos | 0.99284 |
| hueso compacto | 0.416921 |
| neoplasias mieloides | 0.402645 |
| plaquetas maduras | 0.410918 |
| célula madre mieloide | 0.437557 |
| National Cancer Institute | 0.402744 |
| siguientes riesgos | 0.401921 |
| vitamina b12 | 0.403995 |
|
| Instituto Nacional | 0.404912 |
| PDQ Tratamiento | 0.439829 |
| célula madre linfoide | 0.43173 |
| vidrio piezas | 0.403146 |
| neoplasias mielodisplásicas | 0.404775 |
| displasia unilinaje | 0.404747 |
| Physician Data Query | 0.410747 |
| cáncer.ampliar trasplante | 0.403337 |
| leucemia mieloide aguda | 0.59748 |
| célula madre | 0.50311 |
| células sanguÃneas maduras | 0.465531 |
| siguientes pruebas | 0.40454 |
|
CLICK HERE |
| 2025 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer colorrectal (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre las pruebas que se usan para detectar el cáncer colorrectal. |
| PDQ Exámenes | 0.849253 |
| Physician Data Query | 0.949845 |
| sigmoidoscopia causa | 0.801378 |
| tubo recolector | 0.784476 |
| Estados Unidos | 0.979222 |
| riesgos.Los exámenes | 0.85829 |
| cuerpo).ampliar anatomÃa | 0.797555 |
| prevención revisa | 0.744583 |
| radiografÃas llamada | 0.774966 |
|
| PDQ Prevención | 0.956837 |
| pequeño aumento | 0.790999 |
| siguientes exámenes | 0.980519 |
| información ayuda | 0.751125 |
| National Cancer Institute | 0.760892 |
| siguientes riesgos | 0.742979 |
| siguientes sumarios | 0.885224 |
| Instituto Nacional | 0.814155 |
|
CLICK HERE |
| 15774 |
National Cancer Institute |
Html |
en |
Cancer Clinical Trials API |
Access NCI-supported cancer clinical trials information through an application programming interface (API). |
| IND/IDE information | 0.322332 |
| search tools | 0.31747 |
| initial working piece | 0.395837 |
| clinical trial information | 0.444384 |
| application programming interface | 0.438002 |
| developers | 0.217415 |
| CTRP information | 0.321432 |
| questions | 0.217374 |
| Clinical Trials Reporting | 0.43587 |
| NCI-supported cancer | 0.32979 |
| biomarker data | 0.321606 |
| feedback | 0.238876 |
| clinical trial search | 0.427355 |
| database | 0.218238 |
| academia | 0.222589 |
| NCI-specific Data Table | 0.401719 |
| individual communities | 0.317208 |
| contact | 0.217352 |
| large amounts | 0.326709 |
| clinical trials | 0.959644 |
| family members | 0.316516 |
| summary | 0.217584 |
|
| community—advocacy groups | 0.318407 |
| ct-api-support@nih.gov. | 0.306404 |
| Clinical Trials API | 0.843331 |
| beta version | 0.313025 |
| https://clinicaltrialsapi.cancer.gov | 0.217378 |
| meaningful ways | 0.325497 |
| regulatory information | 0.322729 |
| common language | 0.320268 |
| patients | 0.239672 |
| Documentation | 0.217429 |
| digital platforms | 0.317392 |
| public web | 0.304451 |
| help | 0.217404 |
| better search results | 0.40957 |
| cancer clinical trials | 0.743102 |
| IRB approval details | 0.415735 |
| accrual information | 0.335388 |
| oncologists | 0.229097 |
| integrations | 0.227372 |
| providers | 0.219039 |
| Trials Beta API | 0.505116 |
|
CLICK HERE |
| 16829 |
National Cancer Institute |
Html |
en |
Cancer Driver Discovery Program |
null |
| large number | 0.638311 |
| tumor biology | 0.66038 |
| rare driver events | 0.719635 |
| comprehensive genomic characterization | 0.740363 |
| genomic analyses | 0.633135 |
| patient responses | 0.721865 |
| tumor tissues | 0.638276 |
| additional driver mutations | 0.771411 |
| lung cancer | 0.952268 |
| statistical models | 0.628862 |
| statistical power | 0.629897 |
| cancer genomics | 0.65394 |
| recurrent mutations | 0.655852 |
| patients | 0.702611 |
| Genomic Data Commons | 0.762952 |
| clinical trial N0147 | 0.722969 |
| Lung Cancer project | 0.792668 |
| molecular causes | 0.642033 |
| oncogenic process | 0.640394 |
| public health impact | 0.739202 |
| epidermal growth factor | 0.708102 |
| tumor types | 0.658904 |
| Cancer Driver Discovery | 0.8155 |
| DNA sequencing | 0.651327 |
| Cancer Research UK | 0.776689 |
|
| RNA sequence | 0.636519 |
| associated follow-up information | 0.721592 |
| ovarian cancers | 0.639935 |
| better treatment options | 0.776737 |
| clinical outcomes | 0.638824 |
| Foundation Lung Cancer | 0.793933 |
| intratumoral heterogeneity | 0.742723 |
| deeper characterization | 0.652385 |
| TRACERx collaborators | 0.637079 |
| NCI-funded clinical trial | 0.73112 |
| Genome Characterization Pipeline | 0.748856 |
| driver mutations | 0.919706 |
| St. James | 0.824605 |
| Tracking Cancer Evolution | 0.775958 |
| CCG | 0.851349 |
| colon cancer | 0.744767 |
| lung adenocarcinoma | 0.669686 |
| TRACERx study | 0.634122 |
| total RNA sequencing | 0.961331 |
| Cancer Genome Atlas | 0.832019 |
| chemotherapy regimen | 0.639583 |
| particular lung cancer | 0.807795 |
| Central Cancer Treatment | 0.762707 |
| genome sequencing | 0.685209 |
|
CLICK HERE |